Literature DB >> 26261669

Utility of immunohistochemistry with an antibody against MYC at the initial diagnosis of follicular lymphoma, grade 3A, for predicting a more aggressive clinical course: a case report and review of the literature.

Kunimoto Ichikawa1, Nanae Aritaka2, Kanako Ogura3, Masaru Hosone4, Yasunori Ota5, Eriko Sato2, Norio Komatsu6, Takao Hirano2.   

Abstract

Follicular lymphoma (FL) is the most common indolent lymphoma, and associated with the chromosomal translocation t(14;18)(q32;q21). While, FL harboring both BCL2 and MYC translocation at diagnosis is very rare. The evaluation of MYC expression in typical FL at presentation using southern blot, G-banded karyotyping or fluorescence in situ hybridization (FISH) analyses has been described so far. However, there are no reports about the use of immunohistochemistry (IHC) to evaluate MYC protein expression in FL at presentation. Here, we present a FL patient who transformed to a B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma, accompanied by concurrent BCL2, BCL6, and MYC translocations; i.e., triple-hit lymphoma. Paraffin-embedded tissue section-FISH analysis demonstrated that the FL was negative for MYC, but MYC protein expression was subsequently detected in the lymph node specimen obtained at the initial diagnosis using IHC. This case revealed aggressive clinical course and central nervous system involvement. In the literature concerning MYC positive FL five out of 8 patients were dead within 24 months. The detection of MYC protein expression in FL using IHC might be useful to predict more aggressive clinical course.

Entities:  

Keywords:  BCL2; BCL6; MYC; follicular lymphoma; transformation; triple-hit lymphoma

Mesh:

Substances:

Year:  2015        PMID: 26261669      PMCID: PMC4526003     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  16 in total

1.  Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Tina Marie Green; Ken H Young; Carlo Visco; Zijun Y Xu-Monette; Attilio Orazi; Ronald S Go; Ole Nielsen; Ole V Gadeberg; Torben Mourits-Andersen; Mikael Frederiksen; Lars Møller Pedersen; Michael Boe Møller
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes.

Authors:  Izidore S Lossos; Ash A Alizadeh; Maximilian Diehn; Roger Warnke; Yvonne Thorstenson; Peter J Oefner; Patrick O Brown; David Botstein; Ronald Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-19       Impact factor: 11.205

3.  Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.

Authors:  Kojo S J Elenitoba-Johnson; Stephen D Jenson; Robert T Abbott; Robert A Palais; Sandra D Bohling; Zhaosheng Lin; Sheryl Tripp; Paul J Shami; Lai Y Wang; Robert W Coupland; Rena Buckstein; Bayardo Perez-Ordonez; Sherrie L Perkins; Ian D Dube; Megan S Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-19       Impact factor: 11.205

4.  Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas.

Authors:  Gustavo Tapia; Raquel Lopez; Ana M Muñoz-Mármol; José L Mate; Carolina Sanz; Ruth Marginet; José-Tomás Navarro; Josep-Maria Ribera; Aurelio Ariza
Journal:  Histopathology       Date:  2011-10       Impact factor: 5.087

5.  Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms.

Authors:  Andrew J Davies; Andreas Rosenwald; George Wright; Abigail Lee; Kim W Last; Dennis D Weisenburger; Wing C Chan; Jan Delabie; Rita M Braziel; Elias Campo; Randy D Gascoyne; Elaine S Jaffe; Konrad Muller-Hermelink; German Ott; Maria Calaminici; Andrew J Norton; Lindsey K Goff; Jude Fitzgibbon; Louis M Staudt; T Andrew Lister
Journal:  Br J Haematol       Date:  2007-01       Impact factor: 6.998

6.  C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator?

Authors:  Lesley Christie; Neil Kernohan; David Levison; Mark Sales; Joan Cunningham; Karen Gillespie; Paul Batstone; David Meiklejohn; John Goodlad
Journal:  Leuk Lymphoma       Date:  2008-03

7.  Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.

Authors:  M H Kramer; J Hermans; E Wijburg; K Philippo; E Geelen; J H van Krieken; D de Jong; E Maartense; E Schuuring; P M Kluin
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

8.  MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.

Authors:  Anamarija M Perry; Yuridia Alvarado-Bernal; Javier A Laurini; Lynette M Smith; Graham W Slack; King L Tan; Laurie H Sehn; Kai Fu; Patricia Aoun; Timothy C Greiner; Wing C Chan; Philip J Bierman; Robert G Bociek; James O Armitage; Julie M Vose; Randy D Gascoyne; Dennis D Weisenburger
Journal:  Br J Haematol       Date:  2014-02-08       Impact factor: 6.998

9.  Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis.

Authors:  Anuradha Kanungo; L Jeffrey Medeiros; Lynne V Abruzzo; Pei Lin
Journal:  Mod Pathol       Date:  2006-01       Impact factor: 7.842

Review 10.  Chromosomal analyses of 52 cases of follicular lymphoma with t(14;18), including blastic/blastoid variant.

Authors:  A N Mohamed; M Palutke; L Eisenberg; A Al-Katib
Journal:  Cancer Genet Cytogenet       Date:  2001-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.